Design Therapeutics, Inc. Additional Paid in Capital, Common Stock
Design Therapeutics, Inc. (DSGN) had Additional Paid in Capital, Common Stock of $537.43 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-03
- 2026-06-30: Additional Paid in Capital, Common Stock $537.43M.
- 2026-03-31: Additional Paid in Capital, Common Stock $532.96M.
- 2025-12-31: Additional Paid in Capital, Common Stock $509.10M.
- 2025-09-30: Additional Paid in Capital, Common Stock $480.37M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $537.43M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $532.96M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $509.10M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $480.37M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $476.74M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $472.39M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $468.83M 10-K · filed 2026-03-09 |
| 2024-09-30 | $465.10M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $461.98M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $458.45M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $455.25M 10-K · filed 2025-03-10 |
| 2023-09-30 | $452.02M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $448.78M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $444.85M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $441.42M 10-K · filed 2024-03-19 |
| 2022-09-30 | $438.22M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $435.19M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $432.35M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $429.82M 10-K · filed 2023-03-14 |
| 2021-09-30 | $427.95M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $426.68M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $425.44M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $451.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |